Marszalek M, Karim-Kos H, Madersbacher S, et al. Long term overall survival (OS) in patients with primary metastatic kidney cancer: An analysis of 1468 patients from the Austrian National Cancer Registry (ANCR). EMUC 2017, P113.
Alectinib versus crizotinib bij ALK-positief NSCLC
jun 2017 | Longoncologie